25577-04-2 Usage
General Description
1,6,7-Trihydroxyxanthone is a natural compound with a xanthone backbone and three hydroxyl groups attached to different positions on the molecule. It has been isolated from various plants and has demonstrated potential therapeutic properties, including antioxidant, anti-inflammatory, and antitumor activities. Studies have shown that 1,6,7-Trihydroxyxanthone can inhibit the growth of cancer cells and induce apoptosis, making it a promising candidate for the development of anticancer drugs. Additionally, its antioxidant and anti-inflammatory effects suggest potential applications in the treatment of various diseases and conditions. Further research is needed to fully elucidate the pharmacological properties and potential medical uses of 1,6,7-Trihydroxyxanthone.
Check Digit Verification of cas no
The CAS Registry Mumber 25577-04-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,5,7 and 7 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 25577-04:
(7*2)+(6*5)+(5*5)+(4*7)+(3*7)+(2*0)+(1*4)=122
122 % 10 = 2
So 25577-04-2 is a valid CAS Registry Number.
25577-04-2Relevant articles and documents
Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them
Liu, Jie,Zhang, Jianrun,Wang, Huailing,Liu, Zhijun,Zhang, Cao,Jiang, Zhenlei,Chen, Heru
, p. 50 - 61 (2017/04/06)
34 Xanthones were synthesized by microwave assisted technique. Their in?vitro inhibition activities against five cell lines growth were evaluated. The SAR has been thoroughly discussed. 7-Bromo-1,3-dihydroxy-9H-xanthen-9-one (3-1) was confirmed as the most active agent against MDA-MB-231?cell line growth with an IC50 of 0.46?±?0.03?μM. Combination of 3-1 and 5,6-dimethylxanthone-4-acetic acid (DMXAA) showed the best synergistic effect. Apoptosis analysis indicated different contributions of early/late apoptosis and necrosis to cell death for both monomers and the combination. Western Blot implied that the combination regulated p53/MDM2 to a better healthy state. Furthermore, 3-1 and DMXAA arrested more cells on G2/M phase; while the combination arrested more cells on S phase. All the evidences support that the 3-1/DMXAA combination is a better anti-cancer therapy.
